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Summary
Background:  Narcolepsy is a common neuropsychiatric disorder characterized by increased
daytime sleepiness, cataplexy and hypnagogic hallucinations. Deficiency of the hypocretin
neurotransmitter system was shown to be involved in the pathogenesis of narcolepsy in animals
and men. There are several hints that neurodegeneration of hypocretin producing neurons in the
hypothalamus is the pathological correlate of narcolepsy. The ApoE4 allele is a major contributing
factor to early-onset neuronal degeneration in Alzheimer disease and other neurodegenerative
diseases as well.
Methods:  To clarify whether the ApoE4 phenotype predisposes to narcolepsy or associates with
an earlier disease onset, we have genotyped the ApoE gene in 103 patients with narcolepsy and 101
healthy controls.
Results:  The frequency of the E4 allele of the ApoE gene was 11% in the patient and 15% in the
control groups. Furthermore, the mean age of onset did not differ between the ApoE4+ and ApoE4-
patient groups.
Conclusion:  Our results exclude the ApoE4 allele as a major risk factor for narcolepsy.
Background
Narcolepsy is a frequent debilitiating neuropsychiatric
disorder characterized by increased daytime sleepiness,
cataplectic episodes and hypnopompic and hypnagogic
hallucinations. The occurence of narcolepsy is sporadic;
however, a proportion of cases is familial with an auto-
somal-dominant type of inheritance. In contrast to the
normal population with an HLA-DR2 allele frequency of
∼ 30%, over 90% of narcoleptics type HLA-DR2  + and
HLA-DQB1*0602  +[1,2]. The biological significance of
this association remains elusive implicating autoim-
mune aspects in the ethiology [3]. In two animal models
the involvement of the hypocretin (orexin) neurotrans-
mitter system was demonstrated. Murine narcolepsy in-
duced by knocking out the hypocretin gene shows
symptoms corresponding to human narcolepsy [4]. Do-
bermann pincher and Labrador breeds with autosomal
recessively inherited narcolepsy each share a splice-site
mutation in the hypocretin-receptor 2 gene [5]. Al-
though hypocretin levels in CSF of most narcoleptics is
decresed or not detectable [6], no causative mutations in
both hypocretin receptor genes were found in humans. A
single patient with atypical early-onset narcolepsy car-
ries a dominant signal peptide mutation in the prepro-
hypocretin gene [7]. Furthermore a rare sequence
variant in the 5'UTR of preprohypocretin gene has been
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shown to be a risk factor for narcolepsy [8]. Recent re-
ports describe a nearly complete loss of hypocretinergic
neurons in brains of narcoleptic patients as well as scar
tissue normally occupied by the hypocretin-producing
cells [7,9].
Among several neurodegenerative diseases the E4 allele
of the ApoE gene has been recognized as a predisposing
genetic risk factor mainly influencing the age of manifes-
tation of M. Alzheimer. The ApoE protein is a component
of the VLDL particles and chylomicrons and its primary
role is lipid transport [10,11]. The pathophysiological ef-
fect of ApoE4 in neurodegeneration is not clarified yet
and may possibly involve diminished neuroprotection
against amyloid depositions, reactive oxygen species or
exitotoxins [12]. We have tested the hypothesis of the in-
volvement of the E4 allele of ApoE in the etiology of nar-
colepsy.
Methods
Patients were recruited from the University Hospital in
Mainz and St. Josef Hospital in Bochum, Germany. All
but two patients suffered from cataplexies. All patients
fulfilled diagnostic criteria of the Diagnostic and Statis-
tical Manual of Mental Disorders, 4th edition (DSM IV)
and the International Classification of Sleep Disease of
the American Sleep Disorders Association for narcolep-
sy. For further details see Gencik et al. 2000 [8]. The
control group was composed of neurologically investi-
gated 101 healthy individuals. All participants gave writ-
ten, informed consent.
ApoE genotyping was performed as described [13]. The
HLA-DR2 status of the patients was determined previ-
ously. 94 patients typed HLA-DR2+ and 9 patients HLA-
DR2-[8]. Genotype and allele frequencies were com-
pared with the Χ 2-significance test. The age of onset was
known in 60 patients with E4- genotypes and 13 patients
with E4+genotypes, these data were compared by the
Mann Whitney test.
Results and discussion
Until now, only a few factors were recognized to predis-
pose to narcolepsy. It is the major association with the
HLA-DR2 allele on the one hand. Specific TNFα  alleles
[14] as well as the 3250T allele of the preprohypocretin
gene [8] are minor contributors to the etiology on the
other hand. No exogenous risk factors for narcolepsy
have been recognized so far.
Recently, a novel neurotransmitter system was shown to
be involved in narcolepsy in the canine disease model
and in the orexin knock-out mouse. Autopsy reports of
narcoleptic dogs and patients with narcolepsy pointed
out possible neurodegenerative processes in areals with
hypocretin-producing neurons. Taken together, the
pathophysiology of narcolepsy seems to involve an au-
toimmune driven neurodegeneration of yet unkown
cause [3,15].
In order to specify the role of ApoE isoforms in narcolep-
sy, we have determined the allele and genotype frequen-
cies of the E2,  E3 and E4 alleles in patients with
narcolepsy and healthy controls. Allelic and genotypic
frequencies are shown in table 1. No statistically signifi-
cant differences were detected between nacoleptics, the
DR2 subgroups and the controls. Although not signifi-
cant, a tendentially increased E3 frequency was seen
among the DR2+ subgroup of narcoleptics. Furthermore,
in 73 narcoleptics exact age of onset could be deter-
mined. 60 patients had an non-E4, 13 patients had an E4
phenotype. The manifestation ages were 19.6 ± 9.9 years
(mean ± SD) and 21.4 ± 8.6 years for the non-E4 group
and E4 group, respectively. The mean difference of 1.8
years were not statistically signifcant (p = 0.44).
Table 1: Allele and genotype frequencies of the ApoE gene in narcolespy patients and controls.
Patients (n = 103) DR2+ (n = 94) DR2- (n = 9) Controls (n = 91)
Alleles
E2 8%(16) 7.5% (14) 11% (2) 10%(18)
E3 82%(168) 83%(155) 72%(13) 75%(136)
E4 11%(22) 10%(19) 17%(3) 15%(28)
Genotypes
E2/E3 14%(14) 14%(13) 11%(1) 18%(16)
E2/E4 2%(2) 1%(1) 11%(1) 2%(2)
E3/E3 66%(68) 67%(63) 56%(5) 55%(50)
E3/E4 18%(18) 17%(16) 22%(2) 22%(20)
E4/E4 1%(1) 1%(1) / 3%(3)BMC Medical Genetics 2001, 2:9 http://www.biomedcentral.com/1471-2350/2/9
Conclusion
The presented results indicate, that the E4 isotype of the
ApoE protein, which is an important risk factor for com-
plex traits like alzheimer disease, parkinsonism and oth-
er neurodegenerative disorders is not involved in
pathophosiological processes in narcolepsy.
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